Aisling Capital
No summary available yet.
Aisling is the rare healthcare fund where the partners actually know what they're talking about - Dr. Schiff is still practicing medicine and sits on real boards, not just observer seats. Steven Elms brings serious Wall Street pedigree with 60+ transactions under his belt. They take an unusually active approach to investing and actually work closely with portfolio companies to build value and create multiple exit opportunities. The downside? Their flexible investment strategy across everything from seed to LBOs means you're competing with a much wider universe of opportunities for their attention. They're legitimate players with real exits, but don't expect hand-holding if you're just looking for a check.
- —Best for: Clinical-stage biotech founders who want investors with actual medical expertise
- —Watch out for: Broad investment mandate means lots of competition for their attention
- —Known for: Taking board seats and getting deeply involved in value creation
Aisling Capital invests in products, technologies and businesses that advance health. In addition to investing in companies developing pharmaceutical, biotechnology and medical products, Aisling invests in businesses that provide drug development, manufacturing and other important services to the healthcare industry. They believe the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology, leveraging insights from the completion of the human genome and 20 years of developments to expand novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses.
Aisling invests across the life sciences using multiple structures: seed and venture financings of development-stage companies, small-cap publicly traded equities, structured debt and royalty deals and large-cap leveraged buyouts of profitable companies. Their actual portfolio heavily skews to clinical-stage biotech and specialty pharma across oncology, infectious disease, dermatology, respiratory disorders, and women's health.
Joined Aisling in 2000 as a founding managing partner after practicing internal medicine for six years at New York Presbyterian Hospital where he maintains a Clinical Assistant Professor role. Currently serves as a director of Aclaris Therapeutics, Dren Bio, and Monte Rosa Therapeutics. His impressive exit track record includes Biohaven (acquired by Pfizer), Eidos (merged with BridgeBio), and 3-D Pharmaceuticals (acquired by J&J).
Joined Aisling in 2016 and previously served on the Board of Tufts Medical School. Harvard MD with honors and Cornell BA with honors as a College Scholar, plus Luce Fellow and CFA. Brings deep medical credibility with board positions and academic connections that add legitimacy to deals.
Co-founding managing partner who joined in 2000 from Chase H&Q's Life Sciences Investment Banking Group where he was involved in over 60 financing and M&A transactions, helping raise $3.3 billion in capital. The deals guy with serious Wall Street connections and transaction experience.
Have a specific question about Aisling Capital?
Ask Bernie →